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Summary 25 
The anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein not only counteracts apoptosis at 26 
the mitochondria by scaffolding pro-apoptotic Bcl-2-family members, but also acts at 27 
the endoplasmic reticulum, thereby controlling intracellular Ca
2+
 dynamics. Bcl-2 28 
inhibits Ca
2+
 release by targeting the inositol 1,4,5-trisphosphate receptor (IP3R). 29 
Sequence analysis revealed that the Bcl-2-binding site on the IP3R displays strong 30 
homology with a conserved sequence present in all three ryanodine-receptor (RyR) 31 
isoforms. We now report that, Bcl-2 co-immunoprecipitated with RyRs in ectopic 32 
expression systems and in native rat hippocampi, indicating the existence of 33 
endogenous RyR/Bcl-2 complexes. Purified RyR domains containing the putative Bcl-34 
2-binding site bound full-length Bcl-2 in pull-down experiments and interacted with 35 
Bcl-2’s BH4 domain in surface-plasmon-resonance experiments, suggesting a direct 36 
interaction. Exogenous expression of full-length Bcl-2 or electroporation loading of 37 
Bcl-2’s BH4-domain dampened RyR-mediated Ca2+ release in HEK293 cell models. 38 
Finally, introducing the BH4-domain peptide into hippocampal neurons via a patch 39 
pipette decreased RyR-mediated Ca
2+
 release. In conclusion, this study identifies Bcl-2 40 
as a novel inhibitor of RyR-based intracellular Ca
2+
-release channels.  41 
Keywords 42 
Ca
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Introduction 44 
The B-cell lymphoma-2 (Bcl-2) family of proteins consists of both anti- and pro-45 
apoptotic family members. For exerting their function, Bcl-2-family members depend 46 
on the presence of one or more Bcl-2-homology (BH) domains (Letai, 2008). The role 47 
of anti-apoptotic Bcl-2 proteins, which contain four BH domains, as critical gate 48 
keepers of mitochondrial outer-membrane integrity, has been well established (Brunelle 49 
and Letai, 2009; Chipuk and Green, 2008). This is achieved by scaffolding and 50 
neutralizing pro-apoptotic proteins like Bax/Bak and BH3-only proteins via the 51 
hydrophobic cleft, which is formed by the BH3, BH1 and BH2 domains. It has become 52 
increasingly clear that Bcl-2 proteins also modulate intracellular Ca
2+
-signaling events 53 
by directly targeting Ca
2+
-transport mechanisms at different cellular locations. At the 54 
level of the endoplasmic reticulum (ER), the main intracellular Ca
2+
 store, Bcl-2-family 55 
members target the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) (Monaco et al., 56 
2012a; Oakes et al., 2005; Rong et al., 2008; White et al., 2005), sarco/endoplasmic-57 
reticulum Ca
2+
-ATPases (SERCA) (Kuo et al., 1998) and Bax inhibitor 1 (BI-1) (Ahn et 58 
al., 2010; Xu and Reed, 1998). At the mitochondrial outer membranes, Bcl-2 proteins 59 
target the voltage-dependent anion channels (VDAC) (Arbel and Shoshan-Barmatz, 60 
2010; Arbel et al., 2012; Plotz et al., 2012). More recently, Bcl-2 was shown to regulate 61 
plasma-membrane Ca
2+
-ATPase (PMCA) activity (Ferdek et al., 2012). Therefore, Bcl-62 
2’s function in cells seems to be tightly linked to its ability to modulate intracellular 63 
Ca
2+
 homeostasis and dynamics. This is important, given the central role of both Bcl-2 64 
and of Ca
2+
 signaling in cell-fate decisions, mitochondrial bio-energetics, autophagy, 65 
ER stress and apoptosis (Chipuk et al., 2010; Giorgi et al., 2008; Kiviluoto et al., 2013). 66 
Now, recent evidence indicates that the regulation of intracellular Ca
2+
 handling by Bcl-67 
2-family proteins is also important for non-apoptotic functions, including 68 
neuroplasticity, cellular migration, cell-cycle regulation and embryonic development 69 
(Bonneau et al., 2013). 70 
The molecular determinants underlying IP3R/Bcl-2-complex formation have been 71 
identified (Rong et al., 2009; Rong et al., 2008). The BH4 domain of Bcl-2 has been 72 
shown to be responsible for binding to a stretch of 20 amino acids located in the central, 73 
modulatory domain of the IP3R. Moreover, Lys17, located in Bcl-2’s BH4 domain, 74 
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seemed important for its binding to the IP3R and for regulating IP3R-mediated Ca
2+
 75 
release. Lys17 corresponds to Asp11 in the BH4 domain of Bcl-XL and this divergence 76 
underlies a striking functional difference between the BH4-domain biology of Bcl-2 and 77 
Bcl-XL in inhibiting IP3R channels and subsequent Ca
2+
 signaling (Monaco et al., 78 
2012b). Sequence analysis of this Bcl-2-binding site on the IP3R revealed a significant 79 
resemblance to a highly conserved stretch of 22 amino acids present in the ryanodine-80 
receptor (RyR) channels, the other major class of tetrameric intracellular Ca
2+
-release 81 
channels (Lanner et al., 2010).  82 
Guided by this remarkable sequence homology, we now show that Bcl-2, via its BH4 83 
domain, directly targets RyR channels in both ectopic expression systems and native rat 84 
hippocampi, thereby inhibiting RyR-mediated Ca
2+
 release in RyR-expressing cell 85 
models as well as in hippocampal neurons.  86 
87 
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Results 88 
Bcl-2 interacts with RyR channels in HEK293 cell models and in rat hippocampal 89 
brain lysates 90 
The Bcl-2-binding site located in the central modulatory domain of the IP3R (a.a. 1389-91 
1408 for mouse IP3R1) is well characterized (Rong et al., 2008). This binding site 92 
shows great similarity with a region located in the central part of the RyR (a.a. 2448-93 
2469 for rabbit RyR1). Since IP3Rs and RyRs share several binding partners important 94 
for their regulation, it is plausible that Bcl-2 also affects RyR function. In order to verify 95 
this, a co-immunoprecipitation approach in HEK293 cells stably overexpressing either 96 
RyR1 or RyR3 (HEK RyR1 and HEK RyR3 respectively) was first set up. In these 97 
clonal cell lines, RyR levels and endogenous Bcl-2 expression were assessed (Fig. 1A). 98 
RyR1 protein-expression levels were lower compared to RyR3 in their respective cell 99 
lines. The RyR antibody also detected a stable breakdown product of RyR1 and RyR3 100 
resulting in a double signal in the RyR-stained immunoblot as described previously 101 
(Xiao et al., 2002). Interestingly, overexpressing either RyR1 or RyR3 respectively 102 
induced a 2.36 ± 0.30 and 2.77 ± 0.45 (averages ± s.d.) fold increase of endogenous 103 
Bcl-2-protein levels in comparison to the HEK cells stably expressing the empty vector 104 
(HEK mock). Immunoprecipitation of either RyR3 from HEK RyR3 cells (Fig. 1B) or 105 
RyR1 from HEK RyR1 cells (Fig. 1C) resulted in the co-immunoprecipitation of 106 
endogenous Bcl-2 (lanes 1-2) as well as of transiently overexpressed 3XFLAG-Bcl-2 107 
(lanes 3-4). We previously described that the Bcl-2
K17D
 mutant displayed much weaker 108 
binding to the regulatory domain of the IP3R than wild-type Bcl-2 (Monaco et al., 109 
2012b). Yet, 3XFLAG-Bcl-2
K17D
 still co-immunoprecipitated with both RyR3 and 110 
RyR1 proteins (Fig. 1D and E). Next, we examined whether endogenous RyR/Bcl-2 111 
complexes were present in vivo. Hence, lysates from rat hippocampi, which express all 112 
three known RyR isoforms, with RyR2 being the most abundantly expressed isoform 113 
(Martin et al., 1998; Sharp et al., 1993), were prepared. In these lysates, Bcl-2 co-114 
immunoprecipitated with the endogenous RyRs using the pan-RyR antibody, indicating 115 
the presence of endogenous RyR/Bcl-2-protein complexes (Fig. 1F).  116 
 117 
 118 
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Bcl-2 targets the central domain of the different RyR isoforms via its BH4 domain 119 
The previous experiments established that Bcl-2 is found in RyR-protein complexes, but 120 
neither clarified whether Bcl-2 directly binds to RyR channels nor identified the 121 
molecular determinants underlying this interaction. Therefore, we exploited the 122 
previously gained insights into the domains of IP3Rs and Bcl-2 responsible for 123 
IP3R/Bcl-2-complex formation (Monaco et al., 2012a; Monaco et al., 2012b; Rong et 124 
al., 2009). Fig. 2A shows the sequence comparison between the different IP3R and RyR 125 
isoforms, focusing on the known Bcl-2-binding site on the IP3R (Rong et al., 2008). 126 
RyR-protein domains covering approximately 400 a.a. of the central region and 127 
containing the putative Bcl-2-binding site on RyR1, RyR2 and RyR3 (a.a. 2404-2827 128 
for RyR1 (rabbit), a.a 2369-2794 for RyR2 (rabbit) and a.a. 2263-2688 for RyR3 129 
(mink)) were cloned, expressed and purified as recombinant GST-fusion proteins. The 130 
different purified GST-RyR domains were used in GST-pull-down assays, in 131 
combination with cell lysates from COS-1 cells transiently overexpressing 3XFLAG-132 
Bcl-2 (Fig. 2B). The previously characterized domain 3 of the IP3R1 was used as a 133 
positive control (Rong et al., 2009). 3XFLAG-Bcl-2 was pulled down by the IP3R1 134 
domain as well as by the different RyR domains (Fig. 2B). The binding of 3xFLAG-135 
Bcl-2 to the purified GST-RyR domains was consistently higher than its binding to GST 136 
(Supplementary Fig. 1). These data suggest that Bcl-2 interacts with all three RyR 137 
isoforms via a binding site that is located in the central domain of the RyRs. 138 
To assess whether Bcl-2 is able to directly bind to the purified RyR domains and clarify 139 
whether this binding occurs via Bcl-2’s BH4 domain, we performed surface-plasmon-140 
resonance (SPR) experiments. In addition, these data allow for a more quantitative 141 
assessment of the RyR/Bcl-2 interaction. In these experiments, the binding of the 142 
purified GST-RyR domains to a biotinylated version of Bcl-2’s BH4 domain was 143 
monitored. All signals were corrected for background binding to a biotinylated 144 
scrambled BH4 peptide immobilized to another channel on the same chip. Purified 145 
GST-IP3R1 domain 3 (the positive control) and the respective GST-RyR domains were 146 
used as analytes. A concentration-dependent increase in resonance units (RU) indicated 147 
a specific binding to biotin-BH4-Bcl-2 for the GST-IP3R1 domain 3 as well as for the 148 
various GST-RyR domains (Fig. 2C, D). Purified GST did not show significant binding 149 
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to the BH4 domain of Bcl-2 (Fig. 2C). In all cases, the dissociation of the IP3R and RyR 150 
domains from biotin-BH4-Bcl-2 was very slow. Fitted concentration-response curves 151 
(Fig. 2D) were determined and used to obtain approximated EC50 values (Table 1). The 152 
EC50 value for GST-IP3R1 domain 3 (0.38 µM) was very similar to those obtained for 153 
GST-RyR2 domain (0.38 µM) and GST-RyR3 domain (0.37 µM). Only, the binding of 154 
the GST-RyR1 domain seemed to display a lower affinity (EC50 value of 1.53 µM). 155 
This indicated that the BH4 domain of Bcl-2 bound to the RyR2 and RyR3 with nearly 156 
similar affinities as to IP3R1, while the affinity of Bcl-2 binding to RyR1 was lower. 157 
Given that the binding of Bcl-2 to GST-IP3R1 domain 3 is critically dependent on the 158 
presence of Lys17, we also monitored the binding of the different GST-RyR domains to 159 
the biotin-BH4-Bcl-2
K17D
 mutant. The binding of wild-type BH4-Bcl-2 and BH4-Bcl-160 
2
K17D
 to each GST-fusion protein were compared (Fig. 3) and the obtained EC50 values 161 
are presented in Table 1. In agreement with our previous findings (Monaco et al., 162 
2012b), binding of the GST-IP3R1 domain to biotin-BH4-Bcl-2
K17D
 was severely 163 
compromised in comparison to biotin-BH4-Bcl-2. In contrast, the binding of the GST-164 
RyR domains was either not affected (in the case of RyR1) or only slightly affected (in 165 
the case of RyR2 and RyR3).  166 
Collectively, these data indicate that Bcl-2, via its BH4 domain, directly binds to a 167 
central region in all three RyR isoforms. Although the BH4 domain was found to be 168 
responsible for binding to both the RyR and the IP3R, the molecular determinants for 169 
binding to the RyR were not identical to those for binding to IP3Rs. 170 
 171 
Bcl-2 overexpression inhibits RyR-mediated Ca
2+
 release 172 
We next set out to identify possible functional effects of the Bcl-2-RyR interaction. We 173 
performed single-cell [Ca
2+
] measurements to assess the ability of full-size Bcl-2 to 174 
inhibit RyR-mediated Ca
2+
 release in a cellular environment. The empty pCMV24 175 
vector, a 3XFLAG-Bcl-2-or a 3XFLAG-Bcl-2
K17D
-containing vector was co-transfected 176 
with an mCherry-expressing plasmid in HEK RyR3 cells. Fura-2-AM was used as a 177 
cytosolic Ca
2+
 indicator in mCherry-positive cells. All these [Ca
2+
] measurements were 178 
performed in the presence of an extracellular Ca
2+
 chelator (BAPTA) in order to study 179 
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intracellular Ca
2+
-release events. Caffeine concentrations (1.5 mM) generating sub-180 
maximal responses in these cells were used to induce RyR-mediated Ca
2+ 
releases. A 181 
typical experiment showing averaged calibrated single-cell [Ca
2+
] traces of Fura-2-182 
loaded HEK RyR3 cells expressing the empty vector, 3XFLAG-Bcl-2 or 3XFLAG-Bcl-183 
2
K17D 
is shown in Fig. 4A. Overall, overexpression of 3XFLAG-Bcl-2 or 3XFLAG-Bcl-184 
2
K17D
 inhibited the caffeine-induced Ca
2+ 
release by about 30% compared to the empty-185 
vector control in (Fig. 4B). The ER Ca
2+
-store content was measured by blocking 186 
SERCA using 1 µM thapsigargin in the presence of extracellular BAPTA and assessing 187 
the total amount of Ca
2+
 released from the stores (area under the curve). These results 188 
are summarized in Fig. 4C and indicate that overexpression of 3XFLAG-Bcl-2 or 189 
3XFLAG-Bcl-2
K17D 
did not significantly affect the ER Ca
2+
-store content in these cells. 190 
Similar findings were obtained by overexpressing Bcl-2 or the Bcl-2
K17D
 mutant in HEK 191 
RyR1 cells (Supplementary Fig. 2). Because RyR1-expression levels were slightly 192 
lower compared to RyR3 (Fig. 1A) and it was previously reported that, in contrast to the 193 
HEK RyR3 cells, these HEK RyR1 cells are less sensitive to stimulation with caffeine 194 
(Rossi et al., 2002) a higher concentration of caffeine (4.5 mM) was used to obtain 195 
adequate sub-maximal responses. 196 
To verify whether the caffeine-induced Ca
2+
 release was dependent on the RyR, similar 197 
experiments were also performed using HEK mock cells lacking RyRs. Contrary to the 198 
HEK RyR3 cells, administering caffeine did not generate a Ca
2+
 response in HEK mock 199 
cells (Fig. 4D). Addition of 2 µM ionomycin resulted, however, in a rise in cytosolic 200 
[Ca
2+
] in both cell lines, showing that the lack of a caffeine response in HEK mock cells 201 
was due to the absence of RyRs. The ionomycin response was lower in the HEK RyR3 202 
cells due to a partial depletion of the ER Ca
2+
 pool generated by the caffeine response 203 
prior to the addition of ionomycin. 204 
Since Bcl-2 is known to inhibit IP3Rs and Ca
2+ 
release from IP3Rs can activate RyRs via 205 
Ca
2+
-induced Ca
2+
 release, we wanted to exclude that Bcl-2’s inhibitory effect on the 206 
caffeine-induced Ca
2+
 release occurred via an indirect effect on the IP3R. To completely 207 
exclude this possibility, [Ca
2+
] measurements were performed in HEK RyR3 cells in the 208 
presence of 2 µM xestospongin B (XeB), an IP3R inhibitor (Jaimovich et al., 2005). 209 
Overexpression of 3XFLAG-Bcl-2 remained equally potent in inhibiting caffeine-210 
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induced Ca
2+
 release in RyR3-expressing HEK cells in the presence of XeB (and thus 211 
absence of IP3R activity) (Fig. 4E, F). Since Bcl-2 inhibits RyR-mediated Ca
2+
 release 212 
in the presence of a pharmacological IP3R inhibitor and since the Bcl-2
K17D
 mutant is 213 
equally potent in inhibiting RyR-mediated Ca
2+
 release as wild-type Bcl-2, we postulate 214 
that the Bcl-2-mediated inhibition of caffeine-induced Ca
2+ 
release is due to an 215 
inhibition of the RyRs and is not a result of inhibition of IP3Rs or altered ER-store 216 
content. 217 
The BH4 domain of Bcl-2 is sufficient to inhibit RyR-mediated Ca
2+
 release in HEK 218 
RyR3 cells 219 
The single-cell [Ca
2+
] measurements indicated that the RyR/Bcl-2 interaction inhibits 220 
RyR-mediated Ca
2+
 release. In addition, the SPR data (Fig. 2) showed that the Bcl-221 
2/RyR interaction occurs at least in part via the BH4 domain of Bcl-2. We next wanted 222 
to identify whether the BH4 domain of Bcl-2 is sufficient to inhibit RyR channels. 223 
Hence, we measured RyR-mediated Ca
2+
 release in Fluo-3-loaded HEK RyR3 cells 224 
loaded with different concentrations of BH4-Bcl-2 peptide or a scrambled counterpart 225 
(Fig. 5A, B). Entry of the peptide into the cells was mediated by electroporation 226 
loading, as previously described (De Vuyst et al., 2008). Compared to the vehicle 227 
control, electroporation loading of the cells with BH4-Bcl-2 (20 µM) caused a 228 
prominent decrease in the caffeine-induced Ca
2+
 release. Performing the same 229 
experiment with the scrambled BH4-Bcl-2 peptide (20 µM) did not alter caffeine-230 
induced Ca
2+
 release (Fig. 5A). Electroporation loading of increasing concentrations of 231 
BH4-Bcl-2 resulted in a concentration-dependent inhibition of the caffeine-induced 232 
Ca
2+
 release, which was not observed utilizing the scrambled BH4-Bcl-2 (Fig. 5B).  233 
 234 
The BH4 domain of Bcl-2 inhibits RyR-mediated Ca
2+
 release in hippocampal 235 
neuronal cultures 236 
The present data clearly show that the BH4 domain of Bcl-2 is sufficient to bind to and 237 
inhibit RyRs. Since these experiments were all performed in cellular models 238 
overexpressing RyRs, we next wanted to examine whether the BH4 domain of Bcl-2 is 239 
also able to inhibit endogenous RyR channels. Given the presence of endogenous 240 
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RyR/Bcl-2 complexes in rat hippocampal neurons (Fig. 1F), we opted to study the 241 
regulation of RyR channels by the BH4 domain of Bcl-2 in these cells.  242 
Dissociated hippocampal neurons were infected at 7 days in vitro (DIV) with an adeno-243 
associated virus expressing GCaMP3. Single-cell [Ca
2+
] measurements were performed 244 
between 14 and 18 DIV. GCaMP3 was used as a genetically encoded fluorescent Ca
2+
 245 
indicator (Yamada and Mikoshiba, 2012). Utilizing whole-cell voltage-clamp, the 246 
membrane potential was clamped at -60 mV thereby preventing Ca
2+
 influx from the 247 
extracellular space through voltage-gated Ca
2+
 channels. In this way, the measured 248 
changes in fluorescence could be attributed to changes in intracellular Ca
2+
 release and 249 
were not due to Ca
2+
 influx across the plasma membrane. At the same time the BH4 250 
domain of Bcl-2, the scrambled BH4-domain peptide or the vehicle control (DMSO) 251 
were introduced into the neurons via the patch pipette. A scheme of the experimental 252 
protocol is provided in Fig. 6A. Local application of 10 mM caffeine resulted in RyR-253 
mediated Ca
2+
 release. Fig. 6B shows representative images from a time-lapse 254 
experiment and Fig. 6C shows a typical trace obtained for each condition. Introducing 255 
the BH4 domain of Bcl-2 (20 µM) into the soma of the neurons led to a prominent 256 
inhibition of the caffeine-induced Ca
2+
 release compared to introducing either the 257 
vehicle (DMSO) control or the scrambled BH4 domain of Bcl-2 in the neurons (Fig. 258 
6B-D). Pretreatment of the neurons with 50 µM ryanodine almost completely blocked 259 
caffeine-induced Ca
2+
 release indicating that the observed Ca
2+
 release was attributed to 260 
RyR activity (Fig. 6E). Taken together, these data indicate that the BH4 domain of Bcl-261 
2 can inhibit native RyR channels in hippocampal neurons.  262 
  263 
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Discussion 264 
The major finding of this study is that RyR channels, an important class of intracellular 265 
Ca
2+
-release channels, are novel targets for the anti-apoptotic Bcl-2 proteins in both 266 
ectopic RyR-expressing cell systems and primary tissues like the hippocampus. We 267 
showed that Bcl-2 via its BH4 domain directly binds to the central domain of the RyR 268 
channels, thereby suppressing RyR-mediated Ca
2+
 release. These findings clearly 269 
underpin the emerging role for Bcl-2 proteins in intracellular Ca
2+
 signaling by directly 270 
targeting an increasing number of Ca
2+
-transporting systems at intracellular and 271 
plasmalemmal membranes, including IP3Rs (Hanson et al., 2008; Rong et al., 2009; 272 
Rong et al., 2008), SERCA (Kuo et al., 1998), VDAC (Arbel and Shoshan-Barmatz, 273 
2010), BI-1 (Ahn et al., 2010; Xu and Reed, 1998) and PMCA (Ferdek et al., 2012).  274 
The binding of Bcl-2 to the RyR shows a striking resemblance with the binding of Bcl-2 275 
to the IP3R. The latter is interesting because IP3Rs and RyRs show many similarities at 276 
both the structural and functional level (Furuichi et al., 1994; Seo et al., 2012). Both 277 
intracellular Ca
2+
-release channels are modulated by the same cellular factors like Ca
2+
, 278 
ATP and Mg
2+ 
(Bezprozvanny et al., 1991; Bull et al., 2007; Dias et al., 2006; Maes et 279 
al., 2001; Mak and Foskett, 1998). In addition, several kinases target both channels e.g. 280 
PK (protein kinase) A, PKC, PKG and Ca
2+
/calmodulin-dependent protein kinase II 281 
(Furuichi et al., 1994; Lanner et al., 2010; Vanderheyden et al., 2009). Different 282 
regulatory proteins interact with both the IP3Rs and the RyRs. Calmodulin for example 283 
regulates the Ca
2+
 sensitivity of IP3Rs (Kasri et al., 2004) and RyRs (Balshaw et al., 284 
2001). Our data now clearly indicate that, in a similar way as for the IP3R (Rong et al., 285 
2008), RyRs are also targets of Bcl-2. Importantly, the RyRs contain a sequence that has 286 
approximately 60% homology to the Bcl-2-binding site located in the central, 287 
modulatory region of IP3Rs (Rong et al., 2008). Bcl-2 binds to this site on the IP3R 288 
through its BH4 domain (Rong et al., 2009). Our results (Fig. 2) indicate a similar 289 
behavior for Bcl-2 with respect to the RyRs. This similarity extends to the functional 290 
level as binding of the BH4 domain of Bcl-2 leads in both IP3Rs (Rong et al., 2009) and 291 
RyRs to a suppression of channel-mediated Ca
2+
 release.  292 
Sequence alignment revealed a 22 a.a. spanning region (a.a. 2309-2330, mink RyR3) in 293 
the RyR that displays striking homology with the known Bcl-2-binding site of the IP3R. 294 
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In addition, the proposed region is highly conserved across all RyR isoforms of 295 
different species. It can be anticipated that regulation of RyRs by Bcl-2 is important, as 296 
the proposed Bcl-2-binding site on the RyR is already known to be a crucial regulatory 297 
site for RyR-channel stability. Structural coupling (RyR zipping) of this centrally 298 
located site to the N-terminus is critical for adequate RyR functioning (Ikemoto and 299 
Yamamoto, 2002; Yamamoto and Ikemoto, 2002). Disruption of this interaction (RyR 300 
unzipping) generates leaky RyR channels and triggers irregular channel activity. This 301 
central site is also part of a mutational hotspot in RyR1 and RyR2 involved in the onset 302 
of malignant hyperthermia (Hwang et al., 2012) or arrhythmia (Yano, 2008), 303 
respectively. Structural information about this mutational hotspot has been obtained 304 
from 3D cryo-EM studies. In an elegant study, a green fluorescent protein (GFP) tag 305 
was introduced at residue 2367 of RyR2 (Liu et al., 2005), about 60 amino acids 306 
upstream of the here described Bcl-2-binding site. The location of the GFP insert was 307 
mapped to a bridge area between domain 5 and domain 6 (Liu et al., 2005). This area is 308 
known to be located at the cytoplasmic face of the RyR (Radermacher et al., 1994). 309 
Thus, we anticipate that the region where the Bcl-2-binding site is located should be 310 
accessible for interaction. 311 
In addition, a proposed binding site for the 12-kDa and 12.6-kDa FK506-binding 312 
proteins (FKBP12 and FKBP12.6) on the different RyR isoforms is located within the 313 
binding domain for Bcl-2 on the RyRs identified in this study (Brillantes et al., 1994; 314 
Bultynck et al., 2001b; Gaburjakova et al., 2001; Marx et al., 2000; Van Acker et al., 315 
2004). Both FKBP12 and FKBP12.6 are immunophilins tightly associated with the 316 
RyR, necessary for stabilizing the channel (Brillantes et al., 1994). In this way, these 317 
proteins inhibit excessive Ca
2+
 leak via RyRs. Since Bcl-2 targets a site in close 318 
proximity to a FKBP12/FKBP12.6-binding site, it is not surprising that Bcl-2 binding to 319 
RyRs elicits functional consequences. It remains to be determined whether the binding 320 
of immunophilins and Bcl-2-family proteins compete for the same, similar or 321 
overlapping sites and whether RyR/Bcl-2 complexes are present in tissues containing 322 
high levels of FKBP12/FKBP12.6, such as skeletal and cardiac muscle. In any case, 323 
further experiments are needed, since additional FKBP12/FKBP12.6-binding sites on 324 
RyR channels have been proposed. More specifically, for the cardiac RyR2 channel, 325 
FKBP12.6 has been described to bind to both an N-terminal site (Masumiya et al., 326 
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2003) and a C-terminal site (Zissimopoulos and Lai, 2005a; Zissimopoulos and Lai, 327 
2005b). Further experiments investigating competition between Bcl-2 and 328 
FKBP12/FKBP12.6 for the binding to the different RyR isoforms may therefore provide 329 
additional insights in these apparent discrepancies. Furthermore, we previously reported 330 
that despite sequence similarities between the proposed FKBP12-binding site on IP3Rs 331 
and RyRs, their properties and secondary structure may be different (Bultynck et al., 332 
2001a; Bultynck et al., 2001b). Hence, these differences may contribute to the fact that 333 
in IP3Rs this site preferentially binds Bcl-2 over the Bcl-2
K17D 
mutant, whereas for the 334 
equivalent site in the RyRs there was a nearly similar binding of Bcl-2 and Bcl-2
K17D
. 335 
Finally, other factors such as ATP may also influence Bcl-2 binding to the RyR as the 336 
proposed site for Bcl-2 binding in RyRs has also been implicated in ATP binding 337 
(Blayney et al., 2013; Zissimopoulos and Lai, 2005b). 338 
The role of RyRs in cell-survival and cell-death decisions is much less well documented 339 
than for the IP3R. RyRs however can similarly as IP3Rs, also mediate Ca
2+
 signaling 340 
into mitochondria (Hajnoczky et al., 2002). The exact molecular mechanisms of this 341 
Ca
2+
 transfer to the mitochondria remain poorly understood. A recent paper showed that 342 
VDAC2 is coupled to RyR2 in the heart (Min et al., 2012), allowing a direct coupling of 343 
RyR-mediated Ca
2+
 release to Ca
2+
 uptake in the mitochondria. Moreover, RyR-344 
mediated Ca
2+
 signaling has been implicated in ATP production and metabolic 345 
flexibility in the heart (Bround et al., 2013). Other studies implicated RyRs in the 346 
regulation of apoptosis (Kim et al., 2002) and ER stress-mediated cell death (Luciani et 347 
al., 2009; Ruiz et al., 2009) in various cell types, including neurons and pancreatic β 348 
cells. The Bcl-2/RyR interaction described here could therefore provide an important 349 
regulatory mechanism by which RyR activity controls cell fate. Further studies will be 350 
needed to unravel the exact cell biological and/or physiological role of Bcl-2 binding to 351 
RyRs in cell-fate decisions and functions beyond apoptosis. It is becoming increasingly 352 
clear that Ca
2+
 signaling and RyRs play important roles in memory formation and 353 
neurodegenerative diseases (Berridge, 2013; Berridge, 2011). The presence of RyR/Bcl-354 
2 complexes in the hippocampus (Fig. 1F) and the observation that the BH4 domain of 355 
Bcl-2 is able to inhibit RyR-mediated Ca
2+
 release in hippocampal neurons (Fig. 6), 356 
may suggest that Bcl-2, via regulating RyR channels, has an important function in the 357 
brain.   358 
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In conclusion, we identified RyR channels as novel cellular targets for anti-apoptotic 359 
Bcl-2 proteins. Our findings show that Bcl-2 targets and regulates the two main families 360 
of intracellular Ca
2+
-release channels, IP3Rs and RyRs, in a similar way. This further 361 
strengthens the role of Bcl-2 proteins as essential regulators of Ca
2+
-signaling events 362 
and places RyR channels in the growing list of Ca
2+
-transport systems that are targeted 363 
by Bcl-2. 364 
  365 
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Materials and methods 366 
Chemicals, antibodies and peptides 367 
Unless otherwise specified, all chemicals were purchased from Sigma-Aldrich (St. 368 
Louis, MO, USA). XeB was isolated from Xestospongia exigua as previously described 369 
(Quirion et al., 1992). Mouse monoclonal anti-FLAG M2 antibody (1/3000) (Sigma-370 
Aldrich), mouse monoclonal anti-GAPDH antibody (GAPDH-71.1) (1/50000) (Sigma-371 
Aldrich), mouse monoclonal anti-RyR antibody (34C) (1/1000) (Thermo Scientific, 372 
Rockford, IL, USA) and rabbit monoclonal anti-Bcl-2 antibody (1/1000) (50E3) (Cell 373 
Signalling Technology, Boston, MA, USA) were used throughout this study. The 374 
sequences of the peptides used in this study were:  375 
Biotin-BH4-Bcl-2:   Biotin-RTGYDNREIVMKYIHYKLSQRGYEW 376 
Biotin-BH4-Bcl-2
K17D
:
  
Biotin-RTGYDNREIVMDYIHYKLSQRGYEW 377 
Biotin-scrambled BH4-Bcl-2: Biotin-WYEKQRSLHGIMYYVIEDRNTKGYR 378 
These peptides were synthesized by Life Tein (Hillsborough, NJ, USA). The BH4-Bcl-2 379 
and scrambled BH4-Bcl-2 peptides were also obtained without a biotin tag.   380 
Plasmids and constructs 381 
3XFLAG-Bcl-2 and 3XFLAG-Bcl-2
K17D
 were obtained as described previously 382 
(Monaco et al., 2012b). The rabbit RyR1 (7212-8481), RyR2 (7107-8382) and mink 383 
RyR3 (6789-8064) GST-tagged constructs were developed using previously described 384 
methods for cloning (Monaco et al., 2012b), utilizing the BamHI and EcoRI restriction 385 
enzymes and the following primer sets:  386 
RyR1:  Forward: 5’GCGGCGGGATCCCACTTTGGGGAGGAGCCCCCTG3’ 387 
 Reverse: 5’GCGGCGGAATTCCTACCTGGCCTTCTCGATCGTCC3’ 388 
RyR2:  Forward: 5’GCGGCGGGATCCAGCAAAACACTTGATACGGAGGAG 389 
3’ 390 
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 Reverse: 5’GCGGCGGAATTCCTATCGGGTTCTTTCAATCCTCC3’ 391 
RyR3  Forward: 5’GCGGCGGGATCCAAGAGAGAAGTCATGGAGGACGG3’  392 
Reverse:  5’GCGGCGGAATTCCTATTTGGTCCTCTCCACAGACC3’ 393 
Protein purification 394 
GST-fusion-protein purification was performed as described previously (Bultynck et al., 395 
2001b) except for the induction of protein synthesis, which was performed with 0.1 mM 396 
isopropyl β-d-thiogalactoside for 20 hours at 14°C. After the purification, dialysis and 397 
handling of the proteins was performed as described (Monaco et al., 2012b). 398 
Cell culture and transfections 399 
All media and supplements added to the medium used in this paper were purchased 400 
from Life Technologies (Ghent, Belgium).  HEK293 cells stably expressing an empty 401 
pcDNA3.1(-) vector (HEK mock) or stably overexpressing RyR1 or RyR3 (Rossi et al., 402 
2002) were cultured at 37°C in a 5% CO2 incubator in α-Minimum Essential Medium 403 
supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, 404 
2 mM glutamax and 800 µg/ml G418. COS-1 cells were cultured in Dulbecco’s 405 
Modified Eagle’s medium, containing 10% fetal calf serum, 100 IU/ml penicillin, 100406 
μg/ml streptomycin, 2.5 μg/ml fungizone and 2 mM glutamax at 37°C, 10% CO2.  407 
One day after seeding, cells were transiently transfected with either empty p3XFLAG-408 
Myc-CMV-24 or with the same vector containing Bcl-2 or Bcl-2
K17D
. JETprime 409 
transfection reagent (Polyplus Transfections, Illkirch, France) was used according to the 410 
manufacturer’s instruction. Two days later, HEK mock, HEK RyR1 or HEK RyR3 cells 411 
were harvested and lysed using a CHAPS-based lysis buffer (pH 7.5, 50 mM Tris-HCl, 412 
100 mM NaCl, 2 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1% CHAPS and protease 413 
inhibitor tablets (Roche, Basel, Switzerland)). For COS-1 cells a Triton X-100 based 414 
lysis buffer (pH 7.5, 25 mM HEPES, 100 mM NaCl, 1.5 mM MgCl2, 0.5 mM DTT, 415 
10% glycerol, 1% Triton X-100 and protease inhibitor tablets) was used. Cells for 416 
[Ca
2+
] measurements were seeded in 2-chamber slides and transfected two days later 417 
using the X-tremeGENE HP DNA transfection reagent (Roche) according to the 418 
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manufacturer’s protocol. As a selection marker pcDNA 3.1(-) mCherry vector was co-419 
transfected at a 1:3 ratio to the p3XFLAG-Myc-CMV-24 vectors. 420 
Dissociated hippocampal cultures 421 
Dissociated hippocampal neurons were prepared as described previously (Nadif Kasri et 422 
al., 2011). Briefly, embryonic day 18 rat hippocampi were dissected and washed with 423 
ice-cold Hanks’ balanced salt solution (HBSS) without Mg2+ or Ca2+ (Life 424 
Technologies) supplemented with 10 mM HEPES at pH 7.3. Following a 15 min 425 
incubation with 0.25% trypsin at 37ºC, the hippocampi were again washed with the 426 
HBSS solution. After removing the last wash, seeding medium (neurobasal medium 427 
containing 10% FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin and 2% B27 428 
supplement) was added. Using polished Pasteur pipettes the hippocampi were 429 
dissociated and seeded on polyethylene-treated cover slips at 50000 cells/coverslip. 430 
Four hours later, half of the seeding medium was replaced with culturing medium 431 
(neurobasal medium containing 2 mM glutamax, 100 IU/ml penicillin, 100 µg/ml 432 
streptomycin and 2% B27 supplement). Half of the medium was replaced with culturing 433 
medium every three days.  434 
GST-pull downs 435 
The purified GST-fusion proteins or parental GST (0.5 M) were incubated in the 436 
Triton X-100 lysis buffer together with 70 µg of COS-1-cell lysates overexpressing the 437 
3XFLAG-Bcl-2 protein (final volume 500 µl). The incubation was performed at 4°C 438 
using a head-over-head rotator. After 1 hour, the GST-fusion proteins were immobilized 439 
to glutathione-Sepharose® 4B beads (GE Healthcare, Diegem, Belgium). 1.5 to 2 hours 440 
later, the Sepharose beads were washed 5 times using Triton X-100 lysis buffer. 441 
Subsequently, the complexes were eluted in 40 µl 2X LDS (Life Technologies) 442 
supplemented with 1/200 β-mercaptoethanol for 5 min at 95°C. Ten µl of the collected 443 
eluate was used for immunoblot analysis. GelCode Blue (Thermo Scientific) was used 444 
to determine the total amount of protein present on the PVDF membrane (Millipore, 445 
Billerica, MA, USA). For quantification, the amount of 3XFLAG-Bcl-2 bound to the 446 
different GST-fusion proteins was divided by the amount of GST-tagged protein present 447 
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on the membrane corrected for their difference in molecular mass. Values are presented 448 
relative to the amount bound to the positive control, GST-IP3R1 domain 3.  449 
SPR analysis 450 
SPR analysis was performed using a Biacore T100 (GE Healthcare). Immobilization to 451 
the streptavidin-coated sensor chip (BR-1005-31; GE Healthcare) and SPR 452 
measurements were performed as described previously (Monaco et al., 2012b). NaOH 453 
(50 mM) with 0.0026% SDS was used as a regeneration buffer. Dose-response curves 454 
were fitted using the Hill equation. For comparing the binding of the GST-tagged 455 
domains to the wild-type BH4-Bcl-2 and the BH4-Bcl-2
K17D
 mutant, the Vmax of the 456 
fitted curves was fixed to the estimated value for the wild-type BH4 domain for each 457 
GST-fusion domain. 458 
Co-immunoprecipitation experiments 459 
A co-immunoprecipitation kit (Thermo Scientific) was used. Five µg of either the RyR 460 
antibody or a mouse IgG control antibody was covalently immobilized to 20 µl of the 461 
resin according to the manufacturers’ protocol except for the final washing step, which 462 
was performed using the CHAPS-based lysis buffer. Next, when using lysates of cells 463 
overexpressing RyRs and 3XFLAG-Bcl-2 proteins, 200 µg of pre-cleared cell lysate 464 
was incubated overnight at 4°C in CHAPS lysis buffer together with the resin 465 
containing the antibody. For detection of interactions with endogenous Bcl-2 in the 466 
RyR-overexpressing HEK cells, 400 µg of cell lysate was used without prior pre-467 
clearing. The next day, the resin was washed 4-5 times with CHAPS lysis buffer, after 468 
which the elution was performed by boiling the samples for 5 min at 95°C in 50 µl of 469 
2X LDS supplemented with 1/200 β-mercaptoethanol. Twenty-one day-old rat 470 
hippocampi were homogenized in the CHAPS lysis buffer and incubated for 30 min at 471 
4°C. After centrifugation (4000xg) the supernatant was used for co-472 
immunoprecipitation of endogenous Bcl-2/RyR complexes. The same protocol was 473 
used as for the co-immunoprecipitations in the HEK RyR cells with endogenous Bcl-2 474 
with the exception that, the amount of washes was reduced to two.   475 
 476 
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Immunoblot analysis 477 
Samples were prepared and used as previously described (Monaco et al., 2012b). For 478 
visualization of RyRs, NuPAGE 3-8% Tris acetate gels were run. Detection was 479 
performed using Pierce ECL Western Blotting Substrate (Thermo Scientific). For 480 
developing, either CL-Xposure Films (Thermo Scientific) were used in combination 481 
with an X-OMAT 1000 processor (Kodak, Zaventem, Belgium) or a Chemidoc™ MP 482 
system (Bio Rad, Nazareth Eke, Belgium).  483 
Electroporation loading and Ca
2+
 imaging 484 
HEK RyR3 cells were grown as adherent monolayers to near confluency on 18 mm-485 
diameter glass coverslips. Cell cultures were ester-loaded for 45 min with 10 µM Fluo-486 
3-AM (Life Technologies) in HBSS with Ca
2+
 and Mg
2+
 (Life Technologies) 487 
supplemented with 25 mM HEPES (HBSS-HEPES) and 0.01% pluronic F-127 (Life 488 
Technologies) at room temperature, followed by de-esterification for 15 min. 489 
Subsequently, a fine narrow zone of cells was loaded with Bcl-2 peptides and the 490 
fluorescent dye Dextran TEXAS Red (100 µM; Life Technologies) using an in situ 491 
electroporation technique, as described previously (De Vuyst et al., 2008; Decrock et 492 
al., 2009; Monaco et al., 2012b). Briefly, cells were rinsed three times with HBSS-493 
HEPES followed by three washes with a low conductivity electroporation buffer (4.02 494 
mM KH2PO4, 10.8 mM K2HPO4, 1.0 mM MgCl2, 300 mM sorbitol, 2.0 mM HEPES, 495 
pH 7.4). The cells were positioned 400 µm underneath a two-wire Pt-Ir electrode on the 496 
microscopic stage and electroporated in the presence of a tiny amount of electroporation 497 
solution (10 µl). Electroporation was performed with 50 kHz bipolar pulses at a field 498 
strength of 2000 V/cm and applied as 15 trains of 10 pulses of 2 msec duration each. 499 
After electroporation, cells were thoroughly washed with HBSS-HEPES and left 5 min 500 
to recover before proceeding with the Ca
2+
 imaging. For the latter, cells were superfused 501 
for 1 min with HBSS-HEPES, followed by 8 min with 1 mM caffeine in HBSS-HEPES. 502 
Imaging was carried out using an inverted Nikon Eclipse TE300 fluorescence 503 
microscope (Nikon, Brussels, Belgium) equipped with a x40 oil immersion objective 504 
and an EM-CCD camera (QuantEM 512SC, Photometrics, Tuscon, AZ, USA). Images 505 
(1/sec) were generated with custom-developed FluoFrames software written in 506 
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Microsoft Visual C
++
 6.0. Fluorescence-intensity changes in all cells were analyzed with 507 
FluoFrames software. For each individual trace, the relative change of Fluo-3 508 
fluorescence ((F-F0)/F0) was calculated. Subsequently, relative cytoplasmic [Ca
2+
] 509 
changes were quantified as the area under the curve of the separate Ca
2+
 traces.  Data 510 
were normalized to the vehicle (DMSO) condition, which was set as 100%.  511 
Fura-2-AM [Ca
2+
] measurements 512 
A Zeiss Axio Observer Z1 Inverted Microscope equipped with a 20x air objective and a 513 
high-speed digital camera (Axiocam Hsm, Zeiss, Jena, Germany) were used. HEK 514 
RyR1 or HEK RyR3 cells co-transfected with 0.133 µg mCherry and 0.333 µg of the 515 
3XFLAG constructs were loaded, two days after transfection, at room temperature, 516 
using Fura-2-AM (1.25 μM; Biotium, Hayward, CA, USA) in modified Krebs buffer 517 
(135 mM NaCl, 6.2 mM KCl, 1.2 mM MgCl2, 12  mM HEPES, pH 7.3, 11.5 mM 518 
glucose and 2 mM CaCl2). After 30 min, de-esterification was allowed to occur for 30 519 
min at room temperature. Before starting the [Ca
2+
] measurements, mCherry-positive 520 
cells were selected. During the experiment, 3 mM BAPTA (Alfa Aesar, Ward Hill, MA, 521 
USA) was added to buffer extracellular Ca
2+
. Caffeine and thapsigargin (Alomone Labs, 522 
Jerusalem, Israel) responses were measured. For calibration, minimal and maximal 523 
Fura-2 responses were subsequently determined using 2 µM of ionomycin (Enzo Life 524 
Sciences, Farmingdale, NY, USA) supplemented with 50 mM EGTA or 500 mM CaCl2 525 
respectively in modified Krebs buffer. When XeB (2 µM) was used, it was added to the 526 
cell medium one hour prior to Fura-2-AM loading of the cell. XeB was also included 527 
during all steps of the loading process. The cytosolic [Ca
2+
] was calculated using 528 
[Ca
2+
] (nM) = Kd × (F380max/F380min) × (R–Rmin)/(Rmax–R), where Kd is the dissociation 529 
constant of Fura-2 for Ca
2+
 at room temperature (220 nM). In each experiment, 15-20 530 
mCherry-positive cells were measured, which was repeated on at least three different 531 
days. Maximum peak values were calculated for each calibrated trace by subtracting the 532 
baseline [Ca
2+
] from the maximum response, followed by averaging individual data 533 
points. Replicate experiments within the same day were also averaged and used for 534 
obtaining final averages for all days. For thapsigargin experiments the area under the 535 
curve was determined by integrating the curves from the time point when thapsigargin 536 
was added, until calibration was started 10 min later. 537 
21 
 
Hippocampal [Ca
2+
] measurements 538 
One week before measuring, a genetically encoded GCaMP3 Ca
2+ 
indicator was 539 
introduced in the neurons via adenoviral infection. 14 to 18 day-old hippocampal 540 
neurons were used for these experiments. The cover slips were placed in the perfusion 541 
chamber of a Slice Scope microscope (Scientifica, East Sussex, UK). The neurons were 542 
perfused with heated (30ºC), oxygenated artificial cerebrospinal fluid (aCSF) 543 
containing: 124 mM NaCl, 1.25 mM NaH2PO4, 3 mM KCl, 26 mM NaHCO3, 2 mM 544 
CaCl2, 1 mM MgCl2 and 10 mM glucose at pH 7.4. Tetrodotoxin (1 µM) (Tocris 545 
Bioscience, Bristol, UK) was added just before use. Patch pipettes with a 4 MΩ 546 
resistance were pulled from borosilicate capillaries (Science Products GmBH, Hofheim, 547 
Germany). These were filled with the following solution: 115 mM CsMeSO3, 20 mM 548 
CsCl, 10 mM HEPES, 2.5 mM MgCl2, 4 mM Na2-ATP, 0.4 mM Na2-GTP, 10 mM Na-549 
phosphocreatine and 0.1 mM EGTA. The vehicle (DMSO) or 20 µM of either the 550 
scrambled BH4-Bcl-2 or the BH4-Bcl-2 peptide was added to this solution just before 551 
the experiment. Utilizing whole-cell voltage clamp the membrane potential was 552 
clamped at -60 mV using a MultiClamp 700B amplifier (Molecular Devices, Biberach 553 
an der Riss, Germany). After five min of incubation with the peptide the [Ca
2+
] 554 
measurement was started. Using a pneumatic drug-ejection system (PDES-02DX from 555 
NPI, Tamm, Germany), a local  10 mM caffeine puff was administrated after 1 min 556 
through a second patch pipette positioned 15-25 µm from the cell. Imaging was 557 
performed using a CoolLED pE-2 excitation system (Life Sciences & Analytical, 558 
Andover, UK) in combination with an ORCA-Flash2.8 C11440-10C camera 559 
(Hamamatsu, Almere, the Netherlands). HCImage software (Hamamatsu) was used for 560 
analyzing the [Ca
2+
] measurements. 561 
Statistical analysis 562 
When comparing two conditions, two-tailed, unpaired student t-tests were performed. 563 
For comparing three or more groups, repeated measure ANOVA with Bonferroni post 564 
test was performed. * indicates significantly different results when p<0.05. The exact p-565 
values have been indicated in the figures, where feasible.  566 
  567 
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Figure legends 776 
 777 
Figure 1. Bcl-2 interacts with both overexpressed and endogenous RyRs 778 
(A) Immunoblot showing the expression of RyRs, Bcl-2 and GAPDH (loading control) 779 
in cell lysates from empty vector-expressing HEK cells (HEK mock), RyR1-expressing 780 
HEK cells (HEK RyR1) and RyR3-expressing HEK cells (HEK RyR3). (B, C) 781 
Immunoblots from co-immunoprecipitation experiments using HEK RyR3 (B) and 782 
HEK RyR1 (C) cell lysates. RyR3 or RyR1 was immunoprecipitated using a pan-RyR 783 
antibody. Co-immunoprecipitation of endogenous Bcl-2 with RyRs (lanes 1-2) was 784 
assessed via immunoblotting using a Bcl-2 antibody. Co-immunoprecipitation of 785 
ectopically expressed 3XFLAG-Bcl-2 (lanes 3-4) was assessed via immunoblotting 786 
using a FLAG antibody. (D, E lanes 1-2) Similar experiments were performed as in B 787 
and C (lanes 3-4) but utilizing the 3XFLAG-Bcl-2
K17D
 mutant. Immunoprecipitations 788 
using non-specific IgGs were included for every condition to assess the level of non-789 
specific binding. 0.2 and 0.5 µg of total cell lysate was taken as input for the 3XFLAG-790 
tagged proteins and the RyR, respectively (input). (F) Immunoblots showing a typical 791 
co-immunoprecipitation experiment using lysates obtained from 21-day old rat 792 
hippocampi. The endogenous RyRs were immunoprecipitated and the presence of 793 
endogenous Bcl-2/RyR complexes was assessed using a Bcl-2 antibody. The IgG co-794 
immunoprecipitation was used as negative control. 10 µg of total lysates was used as 795 
input. Each experiment was performed at least three times utilizing each time a newly 796 
prepared cell or hippocampal lysate. The double lines in panel B to E indicate were two 797 
parts of the same immunoblot (and same exposure time) were merged. 798 
 799 
Figure 2. Bcl-2 binds to RyRs through its BH4 domain 800 
(A) Sequence alignment of the relevant sites on the three mouse IP3R isoforms (IP3R1: 801 
a.a. 1389-1408, IP3R2: a.a. 1390-1409, IP3R3: a.a. 1380-1499) and the three RyR 802 
isoforms (rabbit RyR1: a.a. 2448-2469, rabbit RyR2: a.a. 2415-2436, mink RyR3: a.a. 803 
2309-2330) based on the known Bcl-2-binding site on the IP3R. Identical (green) or 804 
similar (red) amino acids are indicated. (B) Example of the performed GST-pull-down 805 
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experiments. Top: GelCode Blue staining of an immunoblot showing total amounts of 806 
the pulled-down GST or GST-tagged proteins. Bottom: immunoblot stained with FLAG 807 
antibody showing the amounts of pulled-down 3XFLAG-Bcl-2 protein. GST was used 808 
as a negative control. 0.1 µg of total COS-1 lysates was used as input. The experiments 809 
were repeated at least 5 times using at least 3 different batches of the GST-tagged 810 
domains and each time a new COS-1 cell lysate. (C) Representative, background-811 
corrected sensorgrams obtained from SPR experiments in which biotin-BH4-Bcl-2 812 
immobilized to streptavidin-coated sensor chips was exposed to GST-tagged proteins 813 
(1.1 M) or GST alone (5 M). Binding was expressed in resonance units (RU) as a 814 
function of time. Binding of the GST-fusion proteins to the biotin-BH4-Bcl-2 was 815 
corrected for non-specific binding by subtracting the response of these proteins to the 816 
biotin-scrambled BH4 domain loaded in a different channel on the same sensor chip. 817 
The first arrow indicates the start of the association phase (addition of the GST-fusion 818 
proteins or GST diluted in running buffer), while the second arrow indicates the start of 819 
the dissociation phase (running buffer alone). All experiments were performed using 820 
different sensor chips and at least three different preparations of the GST-tagged 821 
proteins. (D) Averages of the responses to the GST-tagged proteins for each tested 822 
concentration were determined and used to fit dose response-curves. For clarity reasons, 823 
the fitted curve corresponding to the RyR2 domain is depicted here as a dashed line. 824 
Data points indicate averages ± s.e.m. (n=3). 825 
  826 
Figure 3. Comparison of biotin-BH4-Bcl-2 and biotin-BH4-Bcl-2
K17D
 for binding to 827 
the GST-RyR domains 828 
Binding of the different GST-domains to biotin-BH4-Bcl-2 and Biotin-BH4-Bcl-2
K17D
 829 
was compared in SPR experiments similarly performed as in Fig. 2C and D. Biotin-830 
BH4-Bcl-2
K17D
 was immobilized to a different channel on the same sensor chip as 831 
biotin-BH4-Bcl-2. Averages of the responses to the GST-tagged proteins for each 832 
concentration were determined and plotted for both the wild-type BH4-Bcl-2 and the 833 
BH4-Bcl-2
K17D
 mutant. Data points indicate averages ± s.e.m. (n=3). Estimated EC50 834 
values obtained from the fitted dose response-curves are shown in Table 1. 835 
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Figure 4. Overexpression of Bcl-2 inhibits RyR-mediated Ca
2+
 release 836 
Fura-2 loaded, transfected (mCherry-positive) HEK RYR3 cells were selected for 837 
single-cell [Ca
2+
] measurements. (A) Average calibrated [Ca
2+
] traces (20 cells) from 838 
HEK RyR3 cells containing the pCMV24 vector, 3XFLAG-Bcl-2 or 3XFLAG-Bcl-839 
2
K17D
 obtained in one experiment. The administration of BAPTA (3 mM) and caffeine 840 
(1.5 mM) is indicated by the arrows. (B) Quantitative analysis of the caffeine responses 841 
in HEK RyR3 cells; values show averages ± s.e.m. of at least 4 independent 842 
experiments (n>100 cells). (C) Quantitative analysis of the ER Ca
2+
-store content. The 843 
ER Ca
2+
-store content was determined similarly as in panel A, except that thapsigargin 844 
(1 µM) was used instead of caffeine. The area under the curve (AUC) of the calibrated 845 
traces was used for determining the total ER Ca
2+
-store content. The bar graph indicates 846 
the average AUC ± s.e.m. of at least 3 independent experiments (n>80 cells) for each 847 
condition. (D) Average calibrated [Ca
2+
] traces (20 cells) from HEK mock or HEK 848 
RyR3 cells. The administration of caffeine (1.5 mM) and ionomycin (2 µM) is indicated 849 
by the arrows. (E) Typical experiment depicting average calibrated [Ca
2+
] traces (20 850 
cells) from empty-vector control cells and 3XFLAG-Bcl-2-expressing cells showing 851 
caffeine-induced Ca
2+ 
release in the presence of 2 µM of the IP3R inhibitor XeB. The 852 
administration of BAPTA (3 mM) and caffeine (1.5 mM) is indicated by the arrows.  853 
(F) Quantification of the caffeine responses for each condition in the presence of XeB. 854 
Values depict averages of ± s.e.m. of at least 5 independent experiments (n>80 855 
cells/condition).  856 
 857 
Figure 5. The BH4 domain of Bcl-2 is sufficient for inhibiting RyR3-mediated Ca
2+
 858 
release 859 
Single-cell Fluo-3 [Ca
2+
] measurements were performed in HEK RyR3 cells. The 860 
vehicle (DMSO), the BH4 domain of Bcl-2 or the scrambled peptide were loaded via 861 
electroporation (10, 20 or 40 µM), after which 1 mM of caffeine was used as stimulus. 862 
(A) Typical traces obtained for each condition after electroporation loading with 20 µM 863 
of the peptides or the vehicle. The arrow indicates the time where caffeine (1 mM) was 864 
added. The traces are represented as (F-F0)/F0. (B) Quantitative analysis of all 865 
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experiments. Averages of 5 independent experiments are given as relative responses ± 866 
s.e.m. compared to the DMSO control. The caffeine responses were normalized to the 867 
vehicle control. 868 
 869 
Figure 6. The BH4 domain of Bcl-2 inhibits RyR-mediated Ca
2+ 
release in 870 
hippocampal neuronal cultures 871 
Single-cell [Ca
2+
] measurements were performed on 14- to 18-day old dissociated 872 
hippocampal neuronal cultures. GCaMP3-positive cells were selected for the 873 
measurements. The vehicle (DMSO), a scrambled version of the BH4 domain of Bcl-2 874 
(20 µM) or the BH4 domain of Bcl-2 (20 µM) were introduced into the cell via the 875 
patch pipette. At the same time, the membrane potential was clamped at -60 mV. (A) 876 
Scheme of the performed experiment starting from the time when whole-cell voltage-877 
clamp was obtained. Caffeine (10 mM) was locally applied via a second patch pipette 878 
positioned next to the cell. (B) Time lapse of a typical experiment for each tested 879 
condition performed, focusing on the time when caffeine was applied locally. Scale bar, 880 
5 μm. (C) Typical caffeine-induced Ca2+-release responses measured in the soma of one 881 
neuron for each tested condition. The fluorescence was normalized to the baseline 882 
fluorescence and represented as (F-F0)/F0. The arrow indicates the time point when 883 
caffeine was applied. (D) Summary of all performed measurements for the scrambled 884 
BH4 domain of Bcl-2 and the BH4 domain of Bcl-2 normalized to the vehicle control. 885 
The circles indicate the average of all [Ca
2+
] measurements (2 to 4 cells) performed per 886 
condition each day. [Ca
2+
] measurements performed on the same day are indicated in 887 
the same color. The average ± s.e.m. of 6 independent experiments is indicated in black 888 
(n=19 cells for each condition). (E) Typical single-cell [Ca
2+
] measurement performed 889 
in neurons pretreated for 20 min with either the vehicle (DMSO) (black) or 50 µM 890 
ryanodine (grey). The arrow indicates the time point when caffeine was applied. The 891 
fluorescence was normalized to the baseline fluorescence and represented as (F-F0)/F0. 892 
Experiments were performed at least 5 times. 893 
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Table 1: Affinity of biotin-BH4-Bcl-2 and biotin-BH4-Bcl-2
K17D
 
for the used GST-tagged IP3R1 and RyR domains 
 
 
 
 
 
 
 
 
Approximated EC50
 
values obtained from fitting using the 
Hill equation of the data presented in figure 3. 
 
 
 Approximate EC50 values 
(µM) 
BH4 BH4
K17D
 
RyR1 domain 1.53 1.61 
RyR2 domain 0.38 0.80 
RyR3 domain 0.37 0.78 
IP3R1 domain 3 0.38 1.87 
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Quantification of the performed GST-pull downs. Each datapoint indicates binding of 3XFLAG-Bcl-2 to the indicated GST-domain 
normalized to the positive control, GST-IP3R1 domain 3. Pull downs performed during the same experiment are indicated by the same color. 
All individual data points are given together with the median (horizontal bar) (n=5). The grey dashed line indicates the binding of 
3XFLAG-Bcl-2 to the GST-IP3R1 domain 3. 
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Fura-2 loaded, transfected (mCherry-positive) HEK RyR1 cells were selected for single-cell [Ca2+] measurements. (A) Average [Ca2+] traces 
(20 cells) from HEK RyR1 cells containing the pCMV24 vector, 3XFLAG-Bcl-2 or 3XFLAG-Bcl-2K17D obtained in one experiment. The grey and 
black arrows respectively indicate the time points at which BAPTA (3 mM) or caffeine (4.5 mM) was administered. (B) Quantitative analysis of 
the caffeine responses in HEK RyR1 cells; values show averages ± SEM of at least 3 independent experiments (n>80 cells). (C) Quantitative 
analysis of ER Ca2+-store content. The ER Ca2+-store content was determined similarly as in panel A, except thapsigargin (1 µM) was used 
instead of caffeine. The area under the curve (AUC) of the calibrated traces was used for determining the total ER Ca2+-store content. The bar 
graph indicates the average AUC ± SEM of at least 3 independent experiments (n>80 cells) for each condition. 
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